BC
KPTI icon

Birchview Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Birchview Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$468K Buy
+83,952
New +$640K 0.27% 55
2025
Q4 		– Sell
-27,985
Closed -$183K – 76
2025
Q3 		$183K Hold
27,985
– – 0.14% 64
2025
Q2 		$121K Hold
27,985
– – 0.12% 64
2025
Q1 		$105K Sell
27,985
-4
-0% -$34 0.09% 62
2024
Q4 		$284K Sell
27,989
-3,333
-11% -$40.3K 0.23% 50
2024
Q3 		$390K Hold
31,322
– – 0.34% 35
2024
Q2 		$408K Hold
31,322
– – 0.38% 34
2024
Q1 		$709K Hold
31,322
– – 0.58% 29
2023
Q4 		$406K Sell
31,322
-6,800
-18% -$91.6K 0.32% 37
2023
Q3 		$766K Buy
38,122
+18,700
+96% +$420K 0.65% 26
2023
Q2 		$521K Hold
19,422
– – 0.39% 36
2023
Q1 		$1.13M Hold
19,422
– – 0.89% 18
2022
Q4 		$991K Buy
19,422
+1,467
+8% +$102K 0.7% 22
2022
Q3 		$1.47M Hold
17,955
– – 1.04% 20
2022
Q2 		$1.22M Hold
17,955
– – 0.88% 20
2022
Q1 		$1.99M Buy
17,955
+1,555
+9% +$194K 1.43% 13
2021
Q4 		$1.58M Hold
16,400
– – 1.02% 18
2021
Q3 		$1.43M Buy
16,400
+1,067
+7% +$111K 0.97% 19
2021
Q2 		$2.37M Hold
15,333
– – 1.42% 11
2021
Q1 		$2.42M Buy
15,333
+2,800
+22% +$590K 1.44% 13
2020
Q4 		$2.91M Buy
12,533
+1,333
+12% +$309K 1.68% 12
2020
Q3 		$2.45M Hold
11,200
– – 1.64% 10
2020
Q2 		$3.18M Buy
11,200
+1,333
+14% +$394K 1.92% 8
2020
Q1 		$2.84M Buy
9,867
+4,534
+85% +$1.25M 2.52% 7
2019
Q4 		$1.53M Buy
5,333
+666
+14% +$144K 1.12% 10
2019
Q3 		$673K Hold
4,667
– – 0.45% 22
2019
Q2 		$419K Hold
4,667
– – 0.25% 35
2019
Q1 		$409K Hold
4,667
– – 0.26% 35
2018
Q4 		$656K Buy
4,667
+1,334
+40% +$225K 0.62% 20
2018
Q3 		$852K Hold
3,333
– – 0.55% 20
2018
Q2 		$850K Buy
+3,333
New +$824K 0.58% 20

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Birchview Capital's KPTI Position: Q1 2026 in Review

Birchview Capital opened a new position in Karyopharm Therapeutics (KPTI) in Q1 2026: 83,952 shares worth $468K. The stake represents 0.27% of the portfolio and ranks #55 among its holdings. This is a return to the name: Birchview Capital previously reported a position in KPTI as recently as Q3 2025.

Birchview Capital first reported a position in KPTI in Q2 2018 and has held it in 31 quarters since. The position peaked at $3.18M in Q2 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Birchview Capital held 83,952 shares of Karyopharm Therapeutics worth $468K as of Q1 2026.
  • Karyopharm Therapeutics was a new Birchview Capital position in Q1 2026.
  • Karyopharm Therapeutics made up 0.27% of Birchview Capital's portfolio in Q1 2026, its #55 holding.
  • Birchview Capital first reported a position in Karyopharm Therapeutics in Q2 2018 and has held it in 31 quarters since.
  • Birchview Capital's Karyopharm Therapeutics position peaked at $3.18M in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.